Lexapro is owned by Allergan.
Lexapro contains Escitalopram Oxalate.
Lexapro has a total of 4 drug patents out of which 2 drug patents have expired.
Expired drug patents of Lexapro are:
Lexapro was authorised for market use on 14 August, 2002.
Lexapro is available in tablet;oral dosage forms.
The generics of Lexapro are possible to be released after 12 February, 2023.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6916941 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7420069 | ALLERGAN | Crystalline composition containing escitalopram |
Aug, 2022
(5 months ago) | |
US6916941
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(15 days from now) | |
US7420069
(Pediatric) | ALLERGAN | Crystalline composition containing escitalopram |
Feb, 2023
(15 days from now) |
Drugs and Companies using ESCITALOPRAM OXALATE ingredient
Market Authorisation Date: 14 August, 2002
Treatment: NA
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic